Wall Street Wizardry
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

Wall Street Wizardry

Politics

RFK Jr cancels $500 million in mRNA research, HHS to prioritize ‘safer’ vaccine alternatives

by admin August 6, 2025
August 6, 2025
RFK Jr cancels $500 million in mRNA research, HHS to prioritize ‘safer’ vaccine alternatives

A total of 22 mRNA vaccine development contracts totaling roughly $500 million have been canceled, the Department of Health and Human Services (HHS) announced Tuesday.

The mRNA investments were part of the government’s Biomedical Advanced Research and Development Authority (BARDA), a division of HHS that drives some of the country’s most advanced scientific research, such as the development of vaccines, drugs and other tools to fight national health threats. The termination of the 22 BARDA contracts follows a several-weeks-long internal review to determine a path forward when it comes to these investments.

‘We reviewed the science, listened to the experts, and acted,’ HHS Secretary Robert F. Kennedy Jr. said Tuesday. ‘BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We’re shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate.’

In a short video explaining the move, Kennedy said the benefits simply do not outweigh the risks associated with mRNA vaccines. 

Kennedy went on to point out that not only do mRNA vaccines – as shown during the COVID-19 pandemic – not perform well against viruses that infect the upper respiratory tract, but they also do not defend against mutations of the viruses they are intended to go after.

‘This dynamic drives a phenomena called anogenic shift, meaning that the vaccine paradoxically encourages new mutations and can actually prolong pandemics as the virus constantly mutates to escape the protective effects of the vaccine,’ Kennedy said in the video.

For example, the HHS secretary pointed to the omicron variant of the COVID-19 virus, which infected many millions, including those who had been vaccinated against COVID. 

‘A single mutation can make mRNA vaccines ineffective,’ Kebbedy added, noting that the same risks also apply to the flu virus. 

The move to cancel the mRNA contracts under BARDA will not entirely cancel all mRNA vaccine research done by the government, a source familiar with the move indicated. In addition to allowing some final-stage contracts to run their course to completion in an effort to preserve prior taxpayer investments, ongoing mRNA research at the National Institutes of Health (NIH) will not be impacted by this latest move. 

Meanwhile, in lieu of the terminated mRNA research and investments at BARDA, HHS will focus on ‘safer, broader vaccine strategies,’ Kennedy indicated.

‘To replace the troubled mRNA programs, we’re prioritizing the development of safer, broader vaccine strategies like whole virus vaccines and novel platforms that don’t collapse when viruses mutate,’ Kennedy said in his video explanation about the terminated mRNA investments.

During the video, Kennedy reiterated his support for ‘safe, effective vaccines’ for any American who wants them.

‘That’s why we’re moving beyond the limitations of mRNA for respiratory viruses and investing in better solutions.’

This post appeared first on FOX NEWS

previous post
Space-based missile-killing Golden Dome tech aims for crucial test before Trump leaves office: Lockheed Martin
next post
Tim Cook to join Trump at White House for Apple investment announcement

Related Posts

Time for Israel to take out ‘head of...

June 15, 2025

Trump urged to look into US funding of...

February 3, 2025

FBI investigating Iran strike leaker, Leavitt says: ‘They...

June 27, 2025

‘Blatantly unconstitutional’: US judge temporarily blocks Trump’s ban...

January 24, 2025

Waltz’s Signal chat woes snowball as Trump admin...

April 4, 2025

House Democrat announces articles of impeachment against Trump:...

April 29, 2025

Iran will not give up nuclear enrichment, top...

July 22, 2025

Gabbard says Biden admin ignored ‘highly inappropriate’ chats...

February 28, 2025

Elbridge Colby confirmed to top Pentagon policy post...

April 9, 2025

Biden interview audio reveals who brought up Beau’s...

May 18, 2025

    Join our mailing list to get access to special deals, promotions, and insider information. Your exclusive benefits await! Enjoy personalized recommendations, first dibs on sales, and members-only content that makes you feel like a true VIP. Sign up now and start saving!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Netflix shares soar as company reports surging revenue, tops 300 million subscribers

      January 23, 2025
    • 2

      Financial Agreement signed releasing $2M grant

      January 23, 2025
    • 3

      Universal’s ‘Wicked: For Good’ creates a unique marketing challenge

      January 26, 2025
    • 4

      US security contractor will take charge of key checkpoint in Gaza as Israeli forces withdraw

      January 25, 2025
    • 5

      Trump re-designates Iranian-backed Houthis as terrorists: ‘Threaten[s] security of American civilians’

      January 23, 2025
    • 6

      Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

      January 23, 2025
    • 7

      FDA officially authorizes Zyn nicotine pouches for sale following health review

      January 23, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: wallstreetwizardry.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 wallstreetwizardry.com | All Rights Reserved